International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 102 | Views: 170 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Cardiology Science | India | Volume 8 Issue 11, November 2019


Study of Thyroid Dysfunction among Patient with Amiodarone Therapy in Government Stanley Hospital

Manohar G [8] | Murugarajan Singaram [2] | Kannan K [3] | Arun Ranganathan


Abstract: Background: Amiodarone is a potent antiarrhythmic drug that is used to treat ventricular and supraventricular tachyarrhythmias. Clinically relevant thyroid dysfunction is not uncommon during amiodarone therapy, and requires careful diagnosis and treatment. Materials and Methods: We conducted study in the Government Stanley Hospital among the patient attending cardiology OPD. Around 200 subjects were included in this study. All the patients are investigated for thyroid profile and other blood tests and detailed history recorded based on the standard proforma. Results: Thyroid dysfunction occurs in about 27 % of 200 patients who took amiodarone in our study.10 % patients has subclinical hypothyroidism, 2 % has clinical hypothyroidism, 6 % has subclinical thyrotoxicosis, 9 % has clinical thyrotoxicosis. Conclusion: Thyroid dysfunction is very common in our part of country; since our geographical area is mixed with iodine deficient and iodine sufficient population, it is very important to do thyroid function test among patient undergoing chronic Amiodarone Therapy; still larger studies are needed in this area as it is first study in our population, to become it generalised.


Keywords: AIT AMIODARONE INDUCED THYROTOXICOSIS, AIH AMIODARONE INDUCED HYPOTHYROIDISM, TSH, FT4, FT3, AMIODARONE AND THYROID


Edition: Volume 8 Issue 11, November 2019,


Pages: 865 - 868


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top